Lack of effect of corticosteroids and tamoxifen on suramin protein binding and in vitro activity

European Journal of Cancer

Volumn 32, Issue 2, 1996, Pages 311-315

  Driscoll, D L ^a   Steinkampf, R W ^a   Paradiso, L J ^a   Kowal, C D ^a   Klohs, W D ^a  

^a PFIZER INC   (United States)

Author keywords

Corticosteroids; Dexamethasone; Hydrocortisone; Prednisone; Suramin; Tamoxifen

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; PREDNISONE; SURAMIN; TAMOXIFEN;

ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG LABELING; DRUG POTENTIATION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; ISOTOPE LABELING; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; MALE; SURAMIN; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0029935586     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00543-9     Document Type: Article

References (23)

1. Stout TTh, Van Oosterom AT, De Bruijn EA. Interactions between suramin, tamoxifen, and hydrocortisone at the level of plasma protein binding. Proc Am Assoc Cancer Res 1993, 34, 298.
2. McElnay JC, D'Arcy PF. Protein binding displacement interactions and their clinical importance. Drugs 1983, 25, 495-513.
3. Rolan PE. Plasma protein binding displacement interactions-why are they still regarded as clinically important? Br J Clin Pharmacol 1994, 37, 125-128.
4. Eisen MJ. Combined effect of sodium warfarin and phenylbutazone. J Am Med Assoc 1964, 189, 64-65.
5. Aggeler PM, O'Reilly RA, Leong L, Kowitz PE. Potentiation of anticoagulant effect of warafarin by phenylbutazone. New Engl J Med 1967, 276, 496-501.
6. Sellers EM, Koch-Weser J. Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs. Ann NY Acad Sci 1971, 179, 213-225.
7. Sarma GR, Kailasam S, Nair NGK, Narayana ASL, Tripathy SP. Effect of prednisolone and rifampin on isoniazid metabolism in slow and rapid inactivators of isoniazid. Antimicrobial Agents Chemother 1980, 18, 661-666.
8. Boman G. Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid. Eur J Clin Pharmacol 1974, 7, 217-225.
9. Hayakawa T, Kanai N, Yamada R, et al. Effect of steroid hormone on activation of endoxan (cyclophosphamide). Biochem Pharmacol 1969, 18, 129-135.
10. Baer PA, Shore A, Ikeman RL. Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis. Arthritis Rheumatism 1987, 30, 345-347.
11. Edleman J, Potter JM, Hackett LP. The effect of intra-articular steroids on plasma salicylate concentrations. BrJ Clin Pharmacol 1986, 21, 301-307.
12. Klinenberg JR, Miller F. Effect of corticosteroids on blood salicylate concentration. JAMA 1965, 194, 131-134.
13. Stein CA, Saville W, Yarchoan R, et al. Suramin and function of the adrenal cortex. Ann Intern Med 1986, 104, 286-287.
14. Feuillan P, Raffeld M, Stein CA, et al. Effects of suramin on the function and structure of the adrenal cortex in the cynomolgus monkey. J Clin Endocr Metab 1987, 65, 153-158.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72, 248.
16. Gilman AG, Rall TW, Nies AS, Taylor P. The Pharmacological Basis of Therapeutics. New York, Pergamon Press, 1990, 1447.
17. Motzer RJ, Nanus DM, O'Moore P, et al. Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res 1992, 52, 5775-5779.
18. Reed E, Cooper MR, LaRocca RV, Bostick-Bruton F, Myers CE. Suramin in advanced platinum-resistant ovarian cancer. Eur J Cancer 1992, 28A, 864-866.
19. Myers C, Cooper M, Stein C, et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992, 10, 881-889.
20. Eisenberger MA, Reyno LM, Jodrell DI, et al. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst 1993, 85, 611-621.
21. Collins JM, Klecker RW Jr, Yarchoan R, et al. Clinical pharmacokinetics of suramin in patients with HTLV-III infection. J Clin Pharmacol 1986, 26, 22-26.
22. Lopez RL, Peters GJ, van Loenen AC, et al. The effect of schedule protein binding and growth factors on the activity of suramin. Im J Cancer 1992, 51, 921-926.
23. Dewey HM, Wormall A. Studies on suramin (Antrypol, Bayer 205): 6. Further observations on the determination of suramin in whole blood and serum. Biochem J 1948, 43, 24-27.